If there ever was a more urgent time to introduce VelacurTM, that time is now.
By 2030, there will be more than 150 million people in the United States alone that have or are at risk of fatty liver disease, with the majority underdiagnosed.
With VelacurTM, there’s now a practical way to assess millions of people before the onset of advanced disease. VelacurTM enables early diagnosis and management, preventing – and reversing – disease progression and the associated rise in healthcare costs.
VelacurTM quantifies steatosis (fat content) and stages fibrosis (tissue stiffness) in the liver. Our portable solution consists of a handheld ultrasound, which is placed between the patient’s ribs, and an activation pad. The patient lies on the activation pad, which creates steady state waves in the liver and a 3D tissue sample is measured.
The entire procedure takes about 5 minutes to complete, producing immediate and reliable results in determining the health of the liver.
VelacurTM provides an accurate reading of liver health, so physicians have confidence in the diagnosis, treatment and care of their patients.
VelacurTM is a scalable solution for use by physicians at point of care, allowing for broad assessment of patients and those at-risk.
VelacurTM is the most cost-effective in comparison to MRI, biopsy and other diagnostic tools.
VelacurTM offers patients a quick, safe and gentle procedure.
The procedure only takes 5 minutes to perform at point of care and can be delegated by a physician.
Payer pre-authorization is not required, allowing for a same-day procedure with immediate results, increasing practice efficiency and improved patient management.
